News headlines about Cepheid (NASDAQ:CPHD) have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cepheid earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the scientific and technical instruments company an impact score of 45.7220252974546 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
The company has a current ratio of 4.30, a quick ratio of 3.24 and a debt-to-equity ratio of 0.76.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.